Have a personal or library account? Click to login
Human Leukocyte Antigens Class II Alleles Affecting the Response to 5–7 Year Antiretroviral Therapy in A Latvian Cohort Cover

Human Leukocyte Antigens Class II Alleles Affecting the Response to 5–7 Year Antiretroviral Therapy in A Latvian Cohort

Open Access
|Apr 2019

References

  1. Anonymous (2016a). Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: Recommendations for a public health approach. 2nd edn. World Health Organization, Geneva. Available from: http://apps.who.int/iris/bitstream/handle/10665/208825/9789241549684_eng.pdf?sequence=1 (accessed 14 September 2018).
  2. Anonymous (2016b). QIAamp DNA Mini and Blood Mini Handbook. QIAGEN. Sample & Assay Technologies, 5th edn. Available from: https://www.qiagen.com/jp/resources/download.aspx?id=62a200d6-faf4-469b-b50f-2b59cf738962&lang=e (accessed 12 April 2018).
  3. Anonymous (2018). HLA-DRB1, DQ1, DQB1 REAL-TIME PCR Genotyping Kits. DNA-Technology. Available from: http://www.dna-technology.ru/eng/dnaproducts/reagents/ (accessed 12 April 2018).
  4. Balandraud, N., Picard, C., Reviron, D., Landais, C., Toussirot, E., Lambert, N., Telle, E., Charpin, C., Wendling, D., Pardoux, E., Auger, I., Roudier, J. (2013). HLA-DRB1 Genotypes and the Risk of Developing Anti Citrullinated Protein Antibody (ACPA) Positive Rheumatoid Arthritis. PLoS ONE, 8 (5), e64108.10.1371/journal.pone.0064108366784323737967
  5. Boettiger, D.C., Kerr, S., Ditangco, R., Merati, T. P., Pham, T. T. T., Chaiwarith, R., Kiertiburanaku, S., Li, C. K. P., Kumarasamy, N., Vonthanak, S., Lee C., Kinh, N. V., Pujari, S., Wong, W. W., Kamarulzaman, A., Zhang, F., Yunihastuti, E., Choi, J. Y., Oka, S., Ng, O. T., Kantipong P., Mustafa, M., Ratanasuwan, W., Sohn, A., Law, M. (2014). Trends in first-line antiretroviral therapy in Asia: results from the TREAT Asia HIV observational database. PLoS ONE, 9 (9), e106525.10.1371/journal.pone.0106525415361125184314
  6. Buck, D., Cepok, S., Hoffmann, S., Grummel, V., Jochim, A., Berthele, A., Hartung, H.-P., Wassmuth, R., Hemmer, B. (2011). Influence of the HLA-DRB1 genotype on antibody development to Interferon Beta in multiple sclerosis. Arch. Neurol., 68 (4), 480–487.10.1001/archneurol.2011.6521482927
  7. Gezie, L. D., Gelaye, K. A., Worku, A. G., Ayele, T. A., Teshome, D. F. (2017). Time to immunologic recovery and determinant factors among adults who initiated ART in Felege Hiwot Referral Hospital, northwest Ethiopia. BMC Res Notes, 10, 277.10.1186/s13104-017-2602-0551298128705176
  8. Goronzy, J. J., Matteson, E. L., Fulbright, J. W., Kenneth J. Warrington, K. J., Chang-Miller, A., Hunder, G. G., Mason, T. G., Nelson, A. M., Valente, R. M., Crowson, C. S., Erlich, H. A., Reynolds, R. L., Swee, R. G., O’Fallon, W. M., Weyan, C. M. (2004). Prognostic markers of radio-graphic progression in early rheumatoid arthritis. Arthritis Rheum., 50 (1), 43–54.10.1002/art.1144514730598
  9. Haas, D. W., Smeaton, L. M., Shafer, R. W., Robbins, G. K., Morse, G. D., Labbe, L., Wilkinson, G. R., Clifford, D. B., D’Aquila R. T., De Gruttola, V., Pollard, R. B., Merigan, T. C., Hirsch, M. S., George, A. L., Donahue, J. P., Kim, R. B. (2005). Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: An adult aids clinical trials group study. J. Infect. Dis., 192, 1931–1942.10.1086/49761016267764
  10. Julg, B., Moodley, E. S., Qi, Y., Ramduth, D., Reddy, S., Mncube, Z., Gao, X., Goulder, P. J., Detels, R., Ndung’u, T., Walker, B. D., Carrington, M. (2011). Possession of HLA class II DRB1*1303 associates with reduced viral loads in chronic HIV-1 clade C and B infection. J. Infect. Dis., 203, 803–809.10.1093/infdis/jiq122307113121257739
  11. Kapitány, A., Szabó, Z., Lakos, G., Aleksza, M., Végvári, A., Soós, L., Karányi, Z., Sipka, S., Szegedi, G., Szekanecz, Z. (2008). Associations between serum anti-CCP antibody, rheumatoid factor levels and HLA-DR4 expression in Hungarian patients with rheumatoid arthritis. Israel Med. Assoc. J, 10, 32–36.
  12. Keet, I. P. M., Tang, J., Klein, M. R., LeBlanc, S., Enger, C., Rivers, C., Apple R. J., Mann, D., Goedert, J. J., Miedema, F., Kaslow, R. A. (1999). Consistent association of HLA Class I and II and transporter gene products with progression of human immunodeficiency Virus Type 1 infection in homosexual men. J. Infect. Dis., 180, 299–309.10.1086/31486210395843
  13. Keiser, O., MacPhail, P., Boulle, A., Wood, R., Schechter, M., Dabis, F., Sprinz, E., Egger, M., for the ART-LINC Collaboration of the international databases to evaluate AIDS (IeDEA) (2009). Accuracy of WHO CD4 cell count criteria for virological failure of antiretroviral therapy. Trop. Med. Int. Health, 14 (10), 1220–1225.10.1111/j.1365-3156.2009.02338.x372249719624478
  14. Langford, S. E., Ananworanich, J., Cooper, D. A. (2007). Predictors of disease progression in HIV infection: A review. AIDS Res. Ther., 4, 11.10.1186/1742-6405-4-11188753917502001
  15. Lucas, G. M., Chaisson, R. E., Moore, R. D. (1999). Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions. Ann. Intern. Med., 131, 81–87.10.7326/0003-4819-131-2-199907200-00002
  16. Lundgren, J. D., Mocroft, A., Gatell, J. M., Ledergerber, B., Monforte, A., Hermans, F., Goebel, F.-D., Blaxhult, A., Kirk, O., Phillips, A. N., for the EuroSIDA Study Group (2002). A clinically prognostic scoring system for patients receiving highly active antiretroviral therapy: Results from the EuroSIDA study. J. Infect. Dis., 185, 178–187.10.1086/338267
  17. Malhotra, U., Holte, S., Dutta, S., Berrey, M. M., Delpit, E., Koelle, D. M., Sette, A., Corey, L., McElrath, M. J. (2001). Role for HLA class II molecules in HIV-1 suppression and cellular immunity following antiretroviral treatment. J. Clin. Invest., 107, 505–517.10.1172/JCI11275
  18. Mallal, S., Nolan, D., Witt, C., Masel, G., Martin, A. M., Moore, C., Sayer, D., Castley, A., Mamotte, C., Maxwell, D., James, I., Christiansen, F. T. (2002). Association between the presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet, 359, 727–732.10.1016/S0140-6736(02)07873-X
  19. Mellors, J. W., Munoz, A., Giorgi, J. V., Margolick, J. B., Tassoni, C. J., Gupta, P., Kingsley, L. A., Todd, J. A., Saah, A. J., Detels, R., Phair, J. P., Rinaldo, C. P. (1997). Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann. Intern. Med., 126 (12), 946–954.10.7326/0003-4819-126-12-199706150-000039182471
  20. Montarroyos, R. U., Miranda-Filho, C. D., César, C. C., Souza, W. V., Lacerda, H. R., Albuquerque, M. F. P. M., Aguiar, M. F., Ximenes, R. A. A. (2014). Factors related to changes in CD4+ T-cell counts over time in patients living with HIV/AIDS: A multilevel analysis. PLoS ONE, 9 (2), e84276.10.1371/journal.pone.0084276391478524505247
  21. Odafe, S., Torpey, K., Khamofu, H., Ogbanufe, O., Oladele, E. A., Kuti, O., Adedokun, O., Badru, T., Okechukwu, E., Chabikuli, O. (2012). The Pattern of Attrition from an Antiretroviral Treatment Program in Nigeria. PLoS ONE, 7 (12), e51254.10.1371/journal.pone.0051254352176223272094
  22. Pantaleo, G., Fauci, A. S. (1996). Immunopathogenesis of HIV infection. Annu. Rev. Microbiol., 50 (1), 825–854.10.1146/annurev.micro.50.1.8258905100
  23. Patrikar, S., Shankar, S., Kotwal, A., Basannard, D. R., Bhattie, V., Vermaf, R., Mukherj, S. (2017). Predictors of first line antiretroviral therapy failure and burden of second line antiretroviral therapy. Med. J. Armed Forces India, 73, 5–11.10.1016/j.mjafi.2016.09.008522136028123238
  24. Pavlos, R., Mallal, S., Phillips, E. (2012). HLA and pharmacogenetics of drug hypersensitivity. Pharmacogenomics, 13 (11), 1285–1306.10.2217/pgs.12.10822920398
  25. Ranasinghe, S., Cutler, S., Davis, I., Lu, R., Soghoian, D. Z., Qi, Y., Sidney, J., Kranias, G., Flanders, M. D., Lindqvist, M., Kuhl, B., Alter, G., Deeks, S. G., Walker, B. D., Gao, X., Sette, A., Carrington, M., Streeck, H. (2013). Association of HLA-DRB1–restricted CD4+ T cell responses with HIV immune control. Nat. Med., 19, 930–933.10.1038/nm.3229397440823793098
  26. Robbins, G. K., Daniels, B., Zheng, H., Chueh, H., Meigs, J. B., Freedberg, K. A. (2007). Predictors of antiretroviral treatment failure in an urban HIV clinic. J. Acquir. Immune Def. Syndr., 44, 30–37.10.1097/01.qai.0000248351.10383.b7236574517106280
  27. Saah, A. J., Hoover, D. R., Weng, S., Carrington, M., Mellors, J., Rinaldo, C. R., Mann, D., Apple, R., Phair, J. P., Detels, R., O’Brien, S., Enger, C., Johnson, P., Kaslow, R. A., Multicenter AIDS Cohort Study. (1998). Association of HLA profiles with early plasma viral load, CD4+ cell count and rate of progression to AIDS following acute HIV-1 infection. AIDS, 12 (16), 2107–2113.10.1097/00002030-199816000-000059833851
  28. Zanelli, E., Breedveld, F. C., de Vries, R. R. P. (2002). HLA association with autoimmune disease: A failure to protect? Rheumatology, 39, 1060–1066.10.1093/rheumatology/39.10.106011035123
  29. Zhu, P., Zhu, Q., Zhang, Y., Ma, X., Li, Z., Li, J., Chen, J., Luo, L., Ring, H. Z., Ring, R. Z., Su, L. (2013). ABCB1 variation and treatment response in AIDS patients: Initial results of the Henan Cohort. PLoS ONE, 8 (1), e55197.10.1371/journal.pone.0055197355587923372834
DOI: https://doi.org/10.2478/prolas-2019-0014 | Journal eISSN: 2255-890X | Journal ISSN: 1407-009X
Language: English
Page range: 84 - 88
Submitted on: Oct 23, 2018
Accepted on: Feb 18, 2019
Published on: Apr 7, 2019
Published by: Latvian Academy of Sciences
In partnership with: Paradigm Publishing Services
Publication frequency: 6 times per year

© 2019 Vladislavs Jasinskis, Oksana Koļesova, Aleksandrs Koļesovs, Baiba Rozentāle, Inga Ažiņa, Ksenija Kramiča, Ludmila Vīksna, Jeļena Eglīte, published by Latvian Academy of Sciences
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.